首页|哌拉西林他唑巴坦钠联合噻托溴铵粉雾剂治疗支气管扩张症的疗效及对T细胞亚群、炎症因子的影响

哌拉西林他唑巴坦钠联合噻托溴铵粉雾剂治疗支气管扩张症的疗效及对T细胞亚群、炎症因子的影响

扫码查看
目的 探究哌拉西林他唑巴坦钠(PIP/TAZO)联合噻托溴铵(TIO)粉雾剂治疗支气管扩张症的疗效及对T细胞亚群和炎症因子的影响.方法 纳入100例2022年8月至2024年1月期间在自贡市第一人民医院接受治疗的支气管扩张症患者,随机数表法分为TIO组(n=50,采用TIO粉雾剂)和联合组(n=50,在TIO组基础上增加PIP/TAZO).比较两组治疗后的临床疗效、肺功能指标、支气管扩张严重程度指数(BSI)、炎症因子水平和T细胞亚群占比.结果 治疗1个月后,联合组的肺功能指标第一秒用力呼气量(FEV1)、FEV1/用力肺活量(FVC)显著高于TIO组;联合组的BSI评分则显著低于TIO组,差异具有统计学意义(P<0.05);联合组的治疗有效率显著高于TIO组,差异具有统计学意义(P<0.05);治疗后,联合组的C反应蛋白(CRP)、降钙素原(PCT)以及外周血中性粒细胞和淋巴细胞的比值(NLR)的水平显著低于TIO组,差异有统计学意义(P<0.05);联合组的CD4+占比和CD4+/CD8+均显著高于TIO组,CD8+占比显著低于TIO组,差异有统计学意义(P<0.05).结论 PIP/TAZO与TIO粉雾剂联合治疗支气管扩张症具有良好的临床疗效,能有效降低患者支气管扩张程度,改善肺部呼吸功能,减轻呼吸系统的炎症反应.
Efficacy of piperacillin/tazobactam sodium combined with tiotropium bromide powder in?halation in the treatment of bronchiectasis and its effect on T cell subsets and inflamma?tory factors
Objective To investigate the efficacy of piperacillin/tazobactam sodium(PIP/TAZO)combined with tiotropium bromide(TIO)powder inhalation in the treatment of bronchiectasis and its effect on T cell subsets and inflammatory factors.Methods A total of 100 patients with bronchiectasis who received treatment in Zigong First People's Hospital from August 2022 to January 2024 were randomly divided into TIO group(n=50,using TIO powder inhalation)and combination group(n=50,using PIP/TAZO on the basis of the conventional group)by the random number table method.The clinical efficacy,pulmonary function in⁃dexes,bronchiectasis severity index(BSI),inflammatory factors level and T cell subsets proportion were compared between the two groups.Results After one month of treatment,the pulmonary function indexes,including forced expiratory volume in one second(FEV1)and FEV1/forced vital capacity(FVC),were nota⁃bly higher than the TIO group,while the BSI score was significantly lower than the TIO group,with these dif⁃ferences being statistically significant(P<0.05).The effective rate of the combined group was higher than the TIO group,and the difference was statistically significant(P<0.05).Following treatment,the combined group displayed notably reduced levels of C⁃reactive protein(CRP),procalcitonin(PCT)and neutrophil⁃to⁃lympho⁃cyte ratio(NLR)compared to the TIO group,and all the differences were statistically significant(P<0.05).The proportions of CD4+and CD4+/CD8+in the combined group were significantly higher than those in the TIO group,and the proportion of CD8+in the combined group was significantly lower than that in the TIO group,all of which were statistically significant(P<0.05).Conclusion The combination of piperacillin/tazobactam sodium and TIO powder inhalation in the treatment of bronchiectasis has good clinical efficacy,which can ef⁃fectively reduce the degree of bronchiectasis,improve the respiratory function of the lungs,and reduce the in⁃flammatory response of the respiratory system.

PIP/TAZOTIOBronchiectasisT cell subsetsInflammatory factors

吴群华、张美霞、陈泽莲

展开 >

自贡市第一人民医院呼吸与危重症医学科,四川,自贡 643000

哌拉西林他唑巴坦钠 噻托溴铵 支气管扩张症 T细胞亚群 炎症因子

四川医学科研课题项目

S19008

2024

分子诊断与治疗杂志
中山大学

分子诊断与治疗杂志

CSTPCD
影响因子:0.65
ISSN:1674-6929
年,卷(期):2024.16(10)